Loading clinical trials...
Loading clinical trials...
An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
Conditions
Interventions
Rapastinel
Locations
128
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Harmonex, Inc.
Dothan, Alabama, United States
NoesisPharma
Phoenix, Arizona, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Woodland Research Northwest
Rogers, Arkansas, United States
California Pharmaceutical Research Institute, Inc
Anaheim, California, United States
Start Date
February 3, 2017
Primary Completion Date
December 6, 2018
Completion Date
December 6, 2018
Last Updated
June 22, 2020
NCT07227454
NCT05415397
NCT07059234
NCT06396312
NCT06136546
NCT06398496
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions